Skip to main content

Articles

Conference Highlights ASH

Ibrutinib in Combination with Rituximab is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High-Risk Chronic Lymphocytic Leukemia: New, Updated Results of a Phase 2 Trial in 40 Patients

Conference Highlights ASH

Single-Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses in Patients with Chronic Lymphocytic Leukemia with and without Deletion 17p

Conference Highlights ASH

A Multicenter, Phase 4 Observational Study of Ofatumumab in Chronic Lymphocytic Leukemia: A European Research Initiative on CLL (ERIC) Study

Conference Highlights ASH

The Bruton’s Tyrosine Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability of Response in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in an Open-Label Extension Study

Conference Highlights ASH

Ofatumumab + Chlorambucil versus Chlorambucil Alone in Patients with Untreated Chronic Lymphocytic Leukemia: Results of the Phase 3 Study Complement 1 (OMB110911)

Genetics Providing New Insights into Signaling Pathways and Treatment Targets in ALL

Rituximab Maintenance and Radioimmunotherapy Are Cost-Effective After First-Line Therapy in Follicular Lymphoma

Switching from Intravenous to Subcutaneous Rituximab Saves Staff Time and Money

2013 Annual Index

Conference Highlights ASH

Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab versus Bendamustine and Rituximab in Previously Untreated and Physically Fit Patients with Advanced Chronic Lymphocytic Leukemia

Page 156 of 244
Results 1551 - 1560 of 2434